Barchart on MSN

Moderna stock: Is MRNA outperforming the health care sector?

With a market cap of $19.5 billion, Moderna, Inc. (MRNA) is a biotechnology company focused on developing medicines and ...
BioSpace

ASCO: Moderna’s mRNA-based melanoma vaccine shows ‘encouraging’ 5-year survival

When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in ...

Moderna to Present at Upcoming Conference in June 2026

CAMBRIDGE, MA / ACCESS Newswire / June 2, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the ...

Moderna (MRNA) Is Down 5.5% After FDA Sets Flu Vaccine Review, Tightens Lawsuit Venue Rules - What's Changed

On May 6, 2026, Moderna’s board amended its bylaws to require Securities Act of 1933 lawsuits be filed exclusively in US ...

Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...

Moderna's mRNA flu vaccine is more effective than the standard shot in a late-stage trial

Moderna’s mRNA flu vaccine gave more protection against illness than the standard flu shot in a phase 3 clinical trial, according to published results.

Moderna Says It's Researching a Hantavirus Vaccine. The Drugmaker's Stock Is Surging.

AFP / Moderna shares are surging after a report the drugmaker confirmed it's working on a potential hantavirus vaccine. Several people have tested positive for the rare hantavirus on the cruise ship ...

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete ...

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran ...